Paul Krebs, PhD; Scott E. Sherman, MD, MPH
Krebs P, Sherman SE. Review: Varenicline for tobacco cessation does not increase CV serious adverse events. Ann Intern Med. 2012;157:JC2-2. doi: 10.7326/0003-4819-157-4-201208210-02002
Download citation file:
Published: Ann Intern Med. 2012;157(4):JC2-2.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Coronary Risk Factors, Smoking, Tobacco, Alcohol, and Other Substance Abuse.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only